Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities
- PMID: 33783695
- DOI: 10.1007/s11154-021-09631-7
Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities
Abstract
Neuroendocrine tumors (NETs) are multifaceted tumors occurring in a variety of organs and often present as metastatic at the time of diagnosis. Accurate staging is the most significant factor in therapy planning, but it remains a challenge. Imaging is established as the cornerstone for disease detection/diagnosis, staging, and follow up. To accurately assess and monitor tumor burden in patients with NETs, various imaging techniques have been developed and optimized. Current recommendations for the imaging of patients with NETs include a combination of both morphologic (or anatomic) and molecular imaging, but a final choice can be puzzling for clinicians. Recognizing that there is no uniform sequence consensus on the "best" imaging test, and the heterogeneity of technologic availability at different centers, we hope to provide a pictorial review of the different imaging techniques and their role and utility in management of patients with NETs, aimed to provide a practical guide for all clinicians.
Keywords: Computed tomography; Magnetic resonance imaging; Neuroendocrine tumor; Positron emission tomography; Ultrasound.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Similar articles
-
Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls.Endocrinol Metab Clin North Am. 2017 Sep;46(3):795-814. doi: 10.1016/j.ecl.2017.04.008. Epub 2017 Jun 20. Endocrinol Metab Clin North Am. 2017. PMID: 28760239 Review.
-
The radionuclide molecular imaging and therapy of neuroendocrine tumors.Curr Cancer Drug Targets. 2005 Mar;5(2):139-48. doi: 10.2174/1568009053202054. Curr Cancer Drug Targets. 2005. PMID: 15810878 Review.
-
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.Eur J Cancer. 2021 Mar;146:56-73. doi: 10.1016/j.ejca.2021.01.008. Epub 2021 Feb 12. Eur J Cancer. 2021. PMID: 33588146 Free PMC article. Review.
-
Imaging neuroendocrine tumors: Characterizing the spectrum of radiographic findings.Surg Oncol. 2021 Jun;37:101529. doi: 10.1016/j.suronc.2021.101529. Epub 2021 Jan 31. Surg Oncol. 2021. PMID: 33549952 Review.
-
Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.Ann Surg Oncol. 2015 Jul;22(7):2295-301. doi: 10.1245/s10434-015-4471-x. Epub 2015 Mar 19. Ann Surg Oncol. 2015. PMID: 25786743
Cited by
-
Ectopic GHRH production: revisiting a rare cause of acromegaly.Rev Endocr Metab Disord. 2025 Aug;26(4):593-602. doi: 10.1007/s11154-025-09961-w. Epub 2025 Apr 2. Rev Endocr Metab Disord. 2025. PMID: 40169474 Review.
-
The radiologic spectrum of neuroendocrine tumors in emergent care.Rev Endocr Metab Disord. 2025 Apr;26(2):175-186. doi: 10.1007/s11154-024-09940-7. Epub 2025 Jan 2. Rev Endocr Metab Disord. 2025. PMID: 39745542 Review.
-
Diagnostic Anatomic Imaging for Neuroendocrine Neoplasms: Maximizing Strengths and Mitigating Weaknesses.J Comput Assist Tomogr. 2024 Jul-Aug 01;48(4):521-532. doi: 10.1097/RCT.0000000000001615. Epub 2024 Mar 23. J Comput Assist Tomogr. 2024. PMID: 38657156 Free PMC article. Review.
-
Rectal neuroendocrine neoplasms: what the radiologists should know.Abdom Radiol (NY). 2022 Dec;47(12):4016-4031. doi: 10.1007/s00261-022-03474-9. Epub 2022 Mar 14. Abdom Radiol (NY). 2022. PMID: 35288791 Review.
References
-
- Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20(2):187–96. https://doi.org/10.1530/ERC-12-0340 . - DOI - PubMed - PMC
-
- Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15(4):1083–97. https://doi.org/10.1677/ERC-08-0017 . - DOI - PubMed
-
- Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):111–34, viii. https://doi.org/10.1016/j.ecl.2010.12.001 .
-
- Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer. 2018;25(1):R11–29. https://doi.org/10.1530/ERC-17-0269 . - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources